A Mycin DS
Adults: Usually 250 mg every 6 hours, or 500 mg every 12 hours. May increase up to 4 g/day, according to severity of infection.
Upper respiratory tract infections of mild to moderate severity: 250 to 500 mg 4 times a day for 10 days.
Lower respiratory infections of mild to moderate severity: 250 to 500 mg 4 times a day for 10 days.
Respiratory tract infections due to Mycoplasma pneumoniae: 500 mg 6 hours for 5 to 10 days, treat severe infections for up to 3 weeks.
Skin and soft tissue infections of mild to moderate severity: 250 to 500 mg 4 times a day for 10 days.
Pelvic inflammatory diseases (PID), acute due to Neisseria gonorrhoeae: 500 mg 4 times a day for 10 to 14 days.
Urogenital infection during pregnancy caused by Chlamydia trachomatis: 500 mg 4 times daily for 7 days or
250 mg 4 times daily for 14 days.
Urethral, endocervical or rectal infections, uncomplicated: 500 mg 4 times daily for 7 days or
250 mg 4 times daily for 14 days.
Non-gonococcal urethritis: 500 mg 4 times daily for at least 7 days.
Neisseria gonorrhoeae: Uncomplicated urethral, endocervical or rectal infections and in penicillinase producing N. gonorrhoeae(PPNG): 500 mg 4 times a day for 7 days.
Early syphillis (primary, secondary or latent syphillis of < 1 year duration): 500 mg 4 times a day for 14 days.
Severe or chronic diarrhoea: 500 mg 4 times a day for 7 days. Rheumatic fever: 250 mg 2 times daily.
Bacterial endocarditis: 1 g 2 hours prior to procedures, then 500 mg 6 hours after initial dose.
Acne: 500 mg twice daily for 3 months reduced to 250 mg twice for 3 months.
The usual oral dose is 30-50 mg/kg body weight per day in divided doses. For more severe infections, the dose may be doubled.
Alternative Brands to A Mycin DS
- Erythromycin A
- A Mycin
- Erona DS
- E-Rox 500
- Mitrocin DS
- Ethrolex 500
- Mac DS
- Eromycin DS
Susceptible infections, Respiratory tract infections, Enteritis, Pertussis, Trench fever, Chanroid, Chlamydial infections, Diphtheria, Legionnaire's disease, Pneumonia, Sinusitis, Bronchitis, Acne, Rheumatic fever, Neonatal conjunctivitis.
Hypersensitivity; porphyria; hepatic impairment; pregnancy.
Rash, urticaria; nausea, vomiting, GI discomfort; ototoxicity; central neurotoxicity; agranulocytosis; arrhythmias; pancreatitis.
Potentially Fatal: Hepatotoxicity, cholestatic jaundice; raised serum transaminases; eosinophilia.
May decrease plasma levels of valproic acid thus, increasing the risk of seizures. Increased plasma concentrations w/ probenecid.
- Anti-diarrhoeal Antimicrobial drugs
- Infections of the respiratory tract
- Acute otitis media
- Susceptible infections
- Streptococcal pharyngitis/tonsillitis
- Chlamydial infections
- Neonatal Conjunctivitis
- Group A Strep. infections
- Rheumatic fever
- Streptococcal pharyngitis
- Upper and lower respiratory tract infections
- Respiratory tract infections
- Granuloma inguinale
- Cat scratch disease
- Middle ear infections (otitis media)
- Atypical pneumonia
- Throat infections
- Relapsing fever and louse-borne typhus
- Trench fever
- Legionnaire's disease
- Acute necrotising ulcerative gingivitis
- Nongonococcal cervicitis
- Lymphogranuloma venereum
- Mycoplasma pneumoniae
- Ichthyosis and dry skin conditions
- Bacteraemic pneumonia
Increased risk of cholestatic hepatitis when treatment is >10 days or in patients with previous history of erythromycin usage. History of hepatic disorders; arrhythmias; prolonged QT interval; lactation. Monitor liver function. Avoid estolate in liver impairment. Caution when using lactobionate in patients with severe renal impairment. May aggravate muscle weakness in patients with myasthenia gravis.
Mode of Action
Erythromycin inhibits protein synthesis by irreversibly binding to the 50S ribosomal subunit thus blocking the transpeptidation or translocation reactions of susceptible organisms resulting in stunted cell growth.